Filter
1958
Text search:
Drug
Safety
Monitoring
Programme
Featured
230
632
Language
Document type
1096
316
258
131
98
24
16
9
3
2
1
1
Countries / Regions
130
69
67
57
56
52
45
44
40
38
37
37
36
32
30
30
27
20
19
17
16
15
15
13
13
13
11
11
9
9
8
8
8
7
7
7
6
6
6
6
6
5
5
5
5
5
5
5
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
832
187
128
95
91
33
26
Toolboxes
172
161
140
126
70
70
66
50
40
36
32
31
27
26
23
21
20
17
12
10
9
8
8
6
The TB section of the toolkit presents selected (a) programmatic output and (b) outcome and impact indicators for TB. In addition to recommended monitoring programs and measuring the outcomes and impact of TB programs, indicators for the strengtheni
...
This guide provides practical, step-by-step guidance on how to organize, implement, and monitor community-based care for DR TB. It is equally useful for program planning or supervision. The target audience for this guide is TB Program Managers, governments, policy makers, nongovernmental organizatio
...
Guide for coordinators and data collectors - The WHO Operational Package for Assessing, Monitoring and Evaluating Country Pharmaceutical Situations is intended as a useful tool for researchers, policy-makers, planners and others who need to use stan
...
Reach the Unreached - FIND, TREAT, CURE TB, SAVE LIVES
2nd edition
10–21 March 2014
A Manual for Medical Officer
Developed under the Government of India – WHO Collaborative Programme 2008-2009
Accessed: 11.03.2019
UN, international agencies and experts released a groundbreaking report demanding immediate, coordinated and ambitious action to avert a potentially disastrous drug-resistance crisis.
If no action is taken - warns the UN Ad hoc Interagency Coordin
...
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
Evaluation report
September 2014
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping lab
...